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ABSTRACT 
Cardiovascular disease (CVD) is the leading cause of death in the United States.  
Nearly half of the people diagnosed with heart failure (HF) die within 5 years of 
diagnosis.  Brain abnormalities secondary to CVD have been observed in many discrete 
regions, including the hippocampus.  Nearly 25% of patients with CVD also have major 
depressive disorder (MDD), and hippocampal dysfunction is a characteristic of both 
diseases.  In this study, the hippocampus and an area of the hippocampal formation, 
the dentate gyrus (DG), were studied in a canine model of HF.  Using this canine HF 
model previously, we have determined that myocardial infarction with mitral valve 
regurgitation (MI/MR) + spinal cord stimulation (SCS) can preserve cardiac function.  
The goal of this study was to determine if the SCS can also protect the brain in a similar 
fashion.  Both the entire hippocampus and the DG tissues were dissected from canine 
brains and analyzed.  These findings provide strong evidence that, in addition to the 
cardioprotective effects observed previously, SCS following MI/MR induces 
neuroprotective effects in the brain. 
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1. INTRODUCTION 
In the United States, cardiovascular disease (CVD) is the most prominent 
disease and the leading cause of death (21).  Within this population, there are a greater 
percentage of people with psychiatric diseases as compared to the population as a 
whole, and major depressive disorder (MDD) is one of the most prominent (12).  
Between 15-30% of patients who have had a myocardial infarction (MI) are diagnosed 
with MDD, and a greater percentage experiences depressive symptom at some point 
during their lifetime (1).  In the event of an MI, the body experiences oxidative stress, 
which can lead to MDD and a variety of other diseases (17).  The development of MDD 
post-MI increases mortality in CVD patients (12).  Imaging studies in depressed patients 
have demonstrated a reduction in limbic system volume, which is hypothesized to be 
related to apoptosis and reduction in neurogenesis (4).  In studies evaluating brain 
pathology in CVD, the limbic system is a major point of interest and in particular, the 
hippocampus (1).  Inflammatory diseases are associated with higher incidences of MDD, 
and the administration of cytokines is an independent risk factor for depressive 
pathology (3).  After an MI, pro-inflammatory cytokines are released from the 
myocardium and levels of tumor necrosis factor-α, interleukin-1β, and interleukin-6 (IL6) 
are elevated in blood (12).  Cardiac disease progression is hypothesized to have a role 
in depressive symptomatology present in CVD patients, and proinflammatory cytokines 
have been demonstrated to induce atrophy in the hippocampus in an MI animal model 
(1).  Evidence suggesting a pathological link between depression and CVD has been 
shown extensively in animal models for CVD (1, 2).  In an MI rat model,increased stress 
on the forced swim test and alteration of sucrose preference, which is a behavioral test 
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of anhedonia, have been observed  are similar to those observed in models for 
depression, and the degree of these deficits were significantly correlated to the degree 
of hippocampal apoptosis (2).  Interestingly, the administration of the selective serotonin 
reuptake inhibitor (SSRI) antidepressant sertraline prevented apoptosis in the limbic 
system following MI (2).  In addition to hippocampal damage, an increase in caspase-3 
activity (which plays a central role in the execution phase of the cell apoptosis cascade) 
has been observed in other limbic brain regions such as the temporal cortex, amygdala, 
and dentage gyrus (DG), a subregion of the hippocampus (2, 4).   
The subgranular zone (SGZ) of the DG within the hippocampus is one of the two 
regions in the adult mammalian brain where neurogenesis can occur (9).  In MDD, there 
is significant evidence indicating a reduction in neurogenesis, and the increase in 
neurogenesis after the administration antidepressant SSRIs is thought to be a mediating 
factor in disease treatment (4).  Brain derived neurotropic factor (BDNF) is a 
neurotrophic factor involved in cell survival and is reduced in patients MDD, and is 
elevated by antidepressant treatments in the brain (4).  An important modulator in 
neurogenesis is the excitatory amino acid glutamate and the NMDA receptor (10).  Both 
the NR1 and NR2B subunits of the NMDA receptor are expressed in the dentate 
granule cell layer from birth to early postnatal life, underlining the role of excitatory 
amino acids and NMDA receptors in the differentiation of granule neurons (Monyer 
1994).  While the role of the NMDA receptor in neurogenesis is not fully understood, the 
administration of multiple NMDA antagonists has been shown to increase levels of 
neurogenesis in the DG (10).  Suppressing the expression of NR1, a necessary subunit 
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for the NMDA receptor, has been shown to increase cell proliferation in transgenic mice 
(11).   
 Endothelial dysfunction resulting from peripheral inflammation is hypothesized to 
be a mediator in the development of post-MI depression (12).  Blood brain barrier (BBB) 
breakdown has also been observed independently of CVD in patients with MDD and 
has been linked to inflammation (20).  Damage to the BBB can cause leakage and 
lasting cellular damage (14).  In CVD, inflammatory factors that are released have been 
implicated in BBB breakdown (19). 
A characteristic of CVD and the progression of HF is the abnormal activation of 
the sympathetic nervous system (SNS), which is often a result of pro-inflammatory 
cytokine signaling (5).  In the periphery, an increase in SNS activity is associated with a 
variety of pathological changes, included increased heart rate, sodium retention, and 
vasoconstriction (5).  Another component to HF is the activation of the renin-
angiotensin-aldosterone system (RAAS), which contributes to cytokine release in the 
myocardium and endothelial dysfunction (5).  Traditional HF drug therapies aim to 
control the autonomic nervous system (ANS) and particularly sympathetic outflow 
through beta-receptor blockade (15).  Autonomic regulation therapies currently being 
studied for heart failure, such as spinal cord stimulation (SCS), attempt to control the 
ANS by modulating the existing neurochemical system through neural stimulation (16).  
High-frequency dorsal SCS has been shown to reduce infarct size in myocardial 
ischemia and protect against arrhythmias in a heart failure animal model (7).  Thoracic 
SCS has been shown to reduce peripheral sympathetic drive and reduce afferent 
sensory cardiac neuron firing, and the sympatholytic effects of thoracic SCS are 
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hypothesized to be the reason for its efficacy (8).  Interestingly, patients with MDD show 
an alteration in autonomic balance where sympathetic inputs predominate 
parasympathetic inputs, and this is associated with heart-rate variability and baroreflex 
sensitivity (13). 
The aim of this study was to evaluate brain pathologies in areas implicated in 
MDD pathophysiology in an animal model for HF.  Additionally, a goal of this study was 
to determine if high thoracic SCS could protect the central nervous system (CNS) 
similarly to the manner in which it protects the peripheral cardiac nervous system and 
myocardium in HF.  In the brain, gene expression analysis was used to investigate 
pathological differences in regions associated with MDD (hippocampus, DG).  Pathways 
were investigated with significant pathology in both MDD and HF, including apoptosis, 
neurogenesis, endothelial dysfunction, and glutamate toxicity.  Histology was completed 
to qualitatively view differences in the DG and tissue surrounding the BBB between 
treatment groups.  Additionally, area fraction analysis was performed to quantitatively 
determine difference in density of the granule cell layer of the DG in each group of 
canines.  Investigating the complex interactions between the heart, peripheral cardiac 
nervous system, and higher control centers as well as the manner in which modulating 
the autonomic nervous system affects the CNS will allow researchers and clinicians to 
better design therapies and treat diseases of the brain and the heart simultaneously. 
2. METHODS  
2.1 Heart failure model and spinal cord stimulation 
A total of 25 canines were utilized for this study.  Canines were randomly 
assigned to the groups sham control (CO), myocardial infarction with mitral regurgitation 
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(MI/MR), and myocardial infarction with mitral regurgitation and spinal cord stimulation 
(MI/MR + SCS).  For the heart failure groups, myocardial infarction was produced by a 
20 minute critical stenosis (~50%) of the left anterior descending (LAD) coronary artery 
followed by a 90 minute full occlusion and subsequent reperfusion.  For the MI/MR + 
SCS group, a spinal cord stimulation device was implanted during the MI surgery.  Two 
leads were implanted in the T1-T3 and T4-T5 level of the spinal cord and the pulse 
generator was implanted and set to a pulse schedule (50Hz, 200µs).  Two weeks 
following the MI, MR was produced by cutting select chordae on the mitral valve (~20%) 
until appropriate left ventricular end-diastolic pressure was met and an audible murmur 
was induced.  One week following the MR surgery, SCS was activated in the MI/MR + 
SCS group.  Approximately four months post-MI, the canines were terminated.  Control 
canines were maintained for the same period of time.  Canine brain tissues were 
surgically removed, dissected in a cryostat at -20C, and stored at -80C.   
2.2 Brain tissue dissection 
Canine brain tissue blocks from the left temporal cortex were sectioned (50µm) 
using a cryostat microtome.  The ventral hippocampus was collected by punch 
dissection (3.5 mm) for gene expression analysis.  For laser capture microdissection 
(LCM), tissue from the adjacent hippocampal layer was sectioned (10µm) and placed on 
Arcturus PEN Membrane Glass Slides.  After the slides were made, they were 
desiccated for 5 minutes and stored at -80°C for further use.  For histochemical 
processing, the tissue was sectioned coronally (10µm), desiccated overnight, and 
stored at -80°C for further use. 
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2.3 Laser capture microdissection 
The dentate gyrus (DG) of the hippocampus was dissected by laser capture 
microdissection (LCM) using the Veritas Microdissection Instrument Model 704 with 
CapSure Macro Caps.  Settings optimized for the dissection were 50mW pulse power, 
1,700 µsec pulse duration, 11-12 laser power, and 2 µm spot diamater.  Relative 
humidity was maintained at <25%.  The DG was located on the tissue slides by 
comparison to rapid (10 min) cresyl violet stained slides at 10x magnification.  The 
staining to capturing timeframe was limited to 2 hours to ensure high quality RNA.  After 
sample collection, the LCM DG samples were suspended in lysis buffer. 
2.4 Area fraction analysis 
Tissue samples (20 µm) from the hippocampus were stained with Cresyl Violet.  
Two-dimensional areal fraction (AF) was carried out using Image J Software to calculate 
cell density in the DG.  Three nonadjacent slides were selected from equal anatomical 
levels.  Frame-by-frame images of the entire DG were taken with a light microscope at 
40X magnification.  Sizes of the images were set to 342 x 257 µm and arranged to the 
middle of the microscope field and 12-14 images were taken.  The photographs of the 
DG contained portions of the molecular layer and the polymorphic cell layer.  Using 
Image J Software, the DG images were cropped to the same size to only contain the 
granule cell layer.  Prior to analysis, the subjects were arranged into groups with the 
same standard threshold.  The AF was calculated by dividing the Nissel-positive area 
(µm2) from the binary image by the total area of the image frame. 
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2.5 Total RNA purification and cDNA synthesis 
Total RNA was purified from the hippocampus punch tissue and laser captured 
DG followed manufacure protocol.  The RNAques Microkit (Ambion) was used to purify 
total RNA, which included a DNase treatment to remove contaminated genomic DNA.  
Following RNA purification, samples were stored at -80°C.  To synthesis cDNA, the 
Superscript III First-Strand Synthesis Supermix reverse transcriptase kit was used 
(Invitrogen).  Following cDNA synthesis, an RNase treatment was performed to remove 
any contamination of RNA.  
2.6 Primer design and optimization for gene expression assays 
Primers were designed for genes of interest using Integrated DNA Technologies 
PrimerQuest SM Web Server Software (Zuker).  The UNAFold Web Server software 
was also used to predict nucleic acid folding.  Primers were designed to contain a GC 
content of 45-55% and span introns, limiting the amplification of genomic DNA.  RT-
PCR was utilized to optimize the conditions for each primer set using 5-Prime 
MasterMIX (Eppendorf). 
2.7 Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) was used to measure the gene expression of 
target genes.  cDNA samples were screened for genomic DNA contamination by using 
RT minus controls.  A Stratagene MX3000P QPCR System or Biorad MiQ qPCR was 
used for running qPCR reactions.  One microliter of cNDA from each subject was used 
as a template for the reaction, and each reaction was carried out in triplicate.  Gene 
specific primers used for amplification were at a final concentration of 400 nM.  Platinum 
Quantitative PCR SuperMix-UDG (Invitrogen) was used, and the SYBR signal was 
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normalized to the ROX signal.  The cycle threshold (Ct) value was used for 
quantification of gene product, and is determined by the point which fluorescence 
exceeds background fluorescence.  cDNAs from all subjects (CO, MI/MR, MI/MR + 
SCS) were ran on the same plate for each gene of interest.  Each target gene was 
normalized to the geometric mean of two or three control genes. 
2.8 Statistical Analysis  
To analyze gene expression and area fraction results, a one-way analysis of 
variance (ANOVA) followed by a Tukey’s Multiple Comparison Test was conducted.  
3. RESULTS 
3.1 Apoptosis (CASP3)  
To determine the degree of apoptosis in the hippocampus in a heart failure 
animal model, caspase-3 (CASP3) gene expression was measured.  Caspase-3 is a 
protease involved in apoptosis and serves as the final mediator in the apoptotic pathway, 
making it a reasonable biomarker for this pathway.  Through mRNA expression analysis, 
it was determined that there was a significant increase in hippocampal CASP3 
expression in the heart failure group as compared to sham operated controls (+97%; 
p<0.0001).  Additionally, in the heart failure group that received spinal cord stimulation 
(SCS) therapy, CASP3 mRNA levels in the hippocampus were maintained at sham 
control levels (-98%; p<0.0001).  CASP3 mRNA upregulation indicates an increase in 
apoptosis in the MI/MR group that is maintained at control levels in the MI/MR + SCS 
group.  Figure 1. 
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3.2 Blood brain barrier (eNOS, GFAP) 
Blood brain barrier disruption has been observed in cardiac disease, and this 
disruption is observed on the level of endothelial cells.  To investigate endothelial 
dysfunction, endothelial nitric oxide synthase (eNOS) gene expression was measured.  
eNOS dysfunction is characteristic of cardiac disease and can result in deleterious 
vascular and neuronal defects.  Through mRNA expression analysis, it was determined 
that there was a significant increase in hippocampal eNOS expression in the heart 
failure group as compared to sham operated controls (+98%; p=0.0185).  Additionally, 
in the heart failure group that received spinal cord stimulation (SCS) therapy, eNOS 
mRNA levels in were not elevated to the same degree (+61%; ns).  Figure 2.  
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In addition to endothelial cells, astrocytes, a type of glial cell, are essential to the 
maintenance and structure of the blood brain barrier.  Glial dysfunction is observed in a 
variety of psychiatric diseases.  Glial fibrilary acidic protein (GFAP) is a protein 
expressed predominantly in astrocytes, and GFAP expression is an accepted biomarker 
for reactive astrocytes.  Through mRNA expression analysis, the data suggested that 
there was a decrease in hippocampal GFAP expression in the heart failure group as 
compared to sham operated controls (-22%; ns).  This effect did not appear to be 
mitigated by SCS therapy.  These results indicate that the trend in heart failure induced 
GFAP reduction within the hippocampus is not mitigated by SCS.  Figure 3. 
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3.3 Neurogenesis (NMDA, BDNF) 
The dentate gyrus (DG) of the hippocampus is one of the regions where 
neurogenesis can occur in the adult mammalian brain.  A number of biochemical 
pathways influence the dynamic process of neurogenesis, including neurotrophic factors, 
glial cells, and glutamanergic neurons.  Brain derived neutrophic factor (BDNF) is a 
neurotrohic factor related to hippocampal atrophy, stress, and neurogenesis regulation.  
Through mRNA expression analysis, the data suggested that there was a decrease in 
hippocampal BDNF expression in the heart failure group as compared to sham 
operated controls (DATA).  This effect did not appear to be mitigated by SCS therapy.   
Figure 4. 
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N-methyl-D-aspartate receptor (NMDAR) is a glutamate receptor subtype and is 
in high concentrations in the hippocampus and in particular, the DG.  A necessary 
subunit of the NMDAR is NR1, which binds the co-agonist glycine.  To investigate the 
NMDAR function in a heart failure model, NR1 expression was measured from the DG.  
Through mRNA expression analysis, it was determined that there was a disruption in 
DG NR1 expression in the heart failure group as compared to sham operated controls 
(+106%; ns).  Additionally, in the heart failure group that received spinal cord stimulation 
(SCS) therapy, NR1 mRNA expression levels in the hippocampus were maintained at 
sham control levels.  Figure 5. 
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3.4 Area fraction of the dentate gyrus 
Area fractal analysis was used to determine the cell density in the granule cell 
layer of the DG.  It was determined that there was a significant decrease in granule cell 
layer density in the heart failure group as compared to sham operated controls (-35%; 
p=0.0054).  The granule layer cell density was maintained at control levels post-SCS.  
Figure 6. 
 
 
 
 
NEUROMODULATION AND THE HIPPOCAMPUS 	  
	   16	  
3.5 Hippocampus morphology 
Figure 7. 
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3.6 Blood brain barrier morphology 
Figure 8 
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4. DISCUSSION 
This study shows that brain pathologies observed in HF in brain regions 
associated with MDD are mitigated by high thoracic SCS.  This is the first study to 
evaluate brain pathologies after SCS therapy in a heart failure model.  These results 
indicate that SCS has both cardio protective effects and neuro protective effects.  
Volume reduction in limbic regions has been observed in patients with MDD and 
apoptosis observed in the hippocampus in this study provides evidence for overlapping 
pathology in HF (4).  A possible explanation for this observation could that the 
hippocampus is susceptible to oxidative stress damage and has a high concentration of 
glutamate receptors, which can cause neural damage in the event of ischemic induced 
glutamate release (23).  Qualitative histological data on the hippocampus supports the 
observed gene expression changes.  The maintenance of caspase-3 mRNA expression 
levels indicates that SCS prevents HF induced hippocampal apoptosis.  In the MI/MR 
group, there was a significant increase in endothelial nitric oxide synthase (eNOS) 
mRNA expression level in the hippocampus as compared to controls, indicating blood 
brain barrier disruption.  eNOS-derived NO is an antihyperintensive, and functions to 
relax smooth muscle and inhibit platelet aggregation (14).  Whereas the upregulation of 
eNOS mRNA may appear to be positive due to the anti-atherosclerotic properties of NO, 
downstream of mRNA expression, there is an inhibition of eNOS activity (14).  SCS did 
not fully reverse the eNOS dysfunction observed in the heart failure animals, but a trend 
of reduction was observed across the samples.  Hippocampus histology indicates that 
there is damage to the tissue around the blood brain barrier (BBB), and we hypothesize 
that this is due to endothelial dysfunction.  GFAP is expressed in reactive astrocytes, 
NEUROMODULATION AND THE HIPPOCAMPUS 
	   19	  
making it an accepted marker for reactive astrocytes.  While there were no significant 
changes in GFAP mRNA expression across the groups that were studied, a negative 
trend was observed between control and MI/MR groups, and this trend was not altered 
by SCS.  It is likely that by increasing the number of subjects in this study that the 
observed trend would reach statistical significance.  Similarly to GFAP, there were no 
significant changes in BDNF mRNA expression between groups, though there was a 
negative trend between control and MI/MR groups that was not mitigated by SCS.  In 
the DG laser captured sample, NR1 gene expression was measured.  NR1 is a subunit 
of NMDAR, a subtype of glutamate receptor.  A number of studies imply that NR1 
expression is a vital component of the complex process of neurogenesis.  The 
expression levels of NR1 were altered drastically in the MI/MR group as compared to 
controls, and this disruption was prevented by SCS.  Results from AF analysis support 
the hypothesis that the DG and the process of neurogensis are disrupted in HF and 
mitigated by SCS.  These data suggest that in addition to cardioprotective effects, there 
are neuroprotective effects of SCS in brain regions associated with MDD.  Considering 
that many patients develop MDD that have CVD and mortality is increased as a result of 
it, therapies that benefit both the brain and the heart will reduce overall mortality and 
benefit the population. 
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6. SUPPLEMENTAL MATERIALS 
GENE SYMBOL ACCESSION 
NUMBER 
SEQUENCE AMPLICON 
LENGTH (BP) 
TEMPERATURE 
(°C) 
CASP3 NC_006598.3 TCATTATTCAGGCCTGCCGAGGT 
ACAAGAAGTCCGCTTCGACTGGT 
111 67 
GFAP NC_006591.3 GCCCGTCTGGATCTGGAGAGGA 
AGCTCCACATGGACCTGCTGC 
128 64 
BDNF NC_006603.3 GCTGTTGGACGAGGACCAGAAGGT 
GGCTCCAAAGGCACTTGACTGCTG 
105 60 
eNOS NC_006598.3 CACAGTAGCTGTGCTGGCATAC 
GGTACAGGATCTCCGGCCTTA  
105 64 
GRIN1 NC_006591.3 AGAACGTCTCCCTGTCCATCCTC 
CTGCGAGAGTCACACTCCTGGTA 
97 64 
GRIN2B NC_006609.3 CCAATGGCAAGCATGGGAAGAA 
GAGTGATCCCACCGCCATGTA 
95 66 
GAPDH NC_006609.3  TGACACCCACTCTTCCACCTTCGAC 
CACCCGGTTGCTGTAGCCAAATTC 
110 68 
SDHA NC_006616.3  AATCCGTGAAGGCAGAGGCTGTGG 
GCCGTCTCTGAAATGCCAGGCAGA 
111 64 
ACTB NC_006588.3  CACTATTGGCAACGAGCGGTTC  
GTAGTTTCATGGATGCCGCAGGA  
90 68 
18S rRNA AY623831
  
TCGATGCTCTTAGCTGAGTGTCC  
GTAGTTTCATGGATGCCGCAGGA 
125 58 
 
